An oligonucleotide-based cGAS agonist for cancer immunotherapy
A hairpin-shaped oligonucleotide, named Svg3, is engineered to selectively activate cGAS, and thereby eliciting type I IFN responses in mouse and human cells. Svg3 is readily loaded into well-established nanocarriers for efficient delivery into cells and, upon endosome escape, into cytosol where Svg3 binds to cytosolic cGAS. This results in cGAS-Svg3 phase separation and the formation of cGAS-Svg3 liquid-like droplets, in which cGAS is activated by Svg3 to trigger the activation of cGAS-STING signaling pathway and IFN-I responses. In tumor microenvironment, Svg3-loaded nanoparticles (NPs) reduced tumor immunosuppression and enhanced antitumor immunity. Intratumoral vaccination of Svg3 NPs dramatically potentiated the tumor immunotherapeutic efficacy of ICB in multiple syngeneic murine tumor models. Moreover, as an immunostimulant adjuvant co-loaded with peptide antigens in NPs (Svg3 + antigen) NPs, Svg3 potentiated the immunogenicity of peptide antigens to elicit antigen-specific T cell responses for potent tumor combination immunotherapy
Publication
Engineering cGAS-agonistic oligonucleotides as therapeutics and vaccine adjuvants for cancer immunotherapy (2023) Shurong Zhou, et al. bioRxiv. 2023 Jul 13;NA(NA). Figure: F1.| Organism | Group | Word | Match | Source | NCBI Symbol | NCBI ID |
|---|
| Word | Match | MeSH | Name | ChEBI |
|---|
Disease mentions
| Word | Match | MeSH | Name | DOID |
|---|